TCGA-33-6738-01A-11R-1949-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.330
- GLYCOLYSIS+0.310
- KRAS_SIGNALING_DN+0.290
- FATTY_ACID_METABOLISM+0.280
- SPERMATOGENESIS+0.270
- MTORC1_SIGNALING+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- BILE_ACID_METABOLISM+0.230
- PEROXISOME+0.220
- ESTROGEN_RESPONSE_LATE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
- WNT_BETA_CATENIN_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.280
- INFLAMMATORY_RESPONSE-0.270
- MITOTIC_SPINDLE-0.260
- ALLOGRAFT_REJECTION-0.240
- TGF_BETA_SIGNALING-0.240
- KRAS_SIGNALING_UP-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0108_T2_RNA | — | B | 0.862 |
| 2 | TCGA-33-A5GW-01A-11R-A27Q-07 | — | cohortSQ2 | 0.821 |
| 3 | C3L-02349 | — | cohortSQ2 | 0.808 |
| 4 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.804 |
| 5 | MBCProject_0040_T2_RNA | — | C | 0.804 |
| 6 | TCGA-E2-A14O-01A-31R-A115-07 | — | B | 0.800 |
| 7 | TCGA-B6-A0IA-01A-11R-A034-07 | — | B | 0.794 |
| 8 | TCGA-GV-A3QF-01A-31R-A22U-07 | — | — | 0.793 |
| 9 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.787 |
| 10 | MNG42 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |